BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29394136)

  • 21. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
    Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
    Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
    Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
    Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma.
    He C; Huang X; Su X; Tang T; Zhang X; Ma J; Guo X; Lv X
    Cancer Biol Ther; 2017 Nov; 18(11):888-894. PubMed ID: 28121221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
    Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
    J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor cells in whole process management of gastrointestinal stromal tumor in a real-life setting.
    Zhang Q; Xu K; Chen M; Miao Y; Wang N; Xu Z; Xu H
    Saudi J Gastroenterol; 2020; 26(3):160-167. PubMed ID: 32386192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
    Theil G; Fischer K; Weber E; Medek R; Hoda R; Lücke K; Fornara P
    PLoS One; 2016; 11(8):e0158354. PubMed ID: 27479125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer.
    Buim ME; Fanelli MF; Souza VS; Romero J; Abdallah EA; Mello CA; Alves V; Ocea LM; Mingues NB; Barbosa PN; Tyng CJ; Chojniak R; Chinen LT
    Cancer Biol Ther; 2015; 16(9):1289-95. PubMed ID: 26252055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Sci Rep; 2017 Dec; 7(1):17307. PubMed ID: 29229933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of breast cancer metastasis risk using circulating tumor markers: A follow-up study.
    Cetintas S; Tezcan G; Tunca B; Egeli U; Gokgoz MS; Cecener G
    Bosn J Basic Med Sci; 2019 May; 19(2):172-179. PubMed ID: 30242807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection.
    Bayarri-Lara C; Ortega FG; Cueto Ladrón de Guevara A; Puche JL; Ruiz Zafra J; de Miguel-Pérez D; Ramos AS; Giraldo-Ospina CF; Navajas Gómez JA; Delgado-Rodriguez M; Lorente JA; Serrano MJ
    PLoS One; 2016; 11(2):e0148659. PubMed ID: 26913536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    de Kruijff IE; Sieuwerts AM; Onstenk W; Jager A; Hamberg P; de Jongh FE; Smid M; Kraan J; Timmermans MA; Martens JWM; Sleijfer S
    Int J Cancer; 2019 Aug; 145(4):1083-1089. PubMed ID: 30761532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of EGFR Expression in Circulating Tumor Cells.
    Serrano MJ; Alvarez-Cubero MJ; De Miguel Pérez D; Rodríguez-Martínez A; Gonzalez-Herrera L; Robles-Fernandez I; Hernandez JE; Puche JLG; Lorente JA
    Adv Exp Med Biol; 2017; 994():285-296. PubMed ID: 28560681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas.
    Henderson T; Chen M; Darrow MA; Li CS; Chiu CL; Monjazeb AM; Murphy WJ; Canter RJ
    J Surg Res; 2018 Mar; 223():207-214. PubMed ID: 29433875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
    Agelaki S; Kalykaki A; Markomanolaki H; Papadaki MA; Kallergi G; Hatzidaki D; Kalbakis K; Mavroudis D; Georgoulias V
    PLoS One; 2015; 10(6):e0123683. PubMed ID: 26083256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy.
    Zhang D; Zhao L; Zhou P; Ma H; Huang F; Jin M; Dai X; Zheng X; Huang S; Zhang T
    Cancer Cell Int; 2017; 17():6. PubMed ID: 28070168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.